On June 20, Gelunhui reported that Shanghai RAAS Blood Products (002252.SZ) completed the equity transfer and Haier's long-term development enabled a new journey for the company. Haier Group's takeover is expected to empower Shanghai RAAS in various aspects such as expansion and development of plasma stations, operation and management, channel sales, and upstream and downstream industry chains, further opening up the company's growth potential. In addition, Grifols' cooperation continues to deepen, gaining exclusive agency for albumin long-term options. In the next decade, Shanghai RAAS' stability in the exclusive agency of Grifols' albumin business will be further improved. Continue to recommend a “buy” rating.
研报掘金丨中邮证券：上海莱士股权转让正式落地，公司开启新征程
Research reports | China Post Securities: Shanghai Raas Blood Products' equity transfer officially landed, and the company embarked on a new journey.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.